Novo Nordisk : GLP-1 market is buoyant
>Top-line growth of 38% and EBIT growth of 47% in Q3 - In mid-October, Novo Nordisk pre-published both its Q3 growth figures and an upward revision of its 2023 guidance. The group's total sales came to DKK 58.731bn, up 38% cc (29%/33% cc over 9M). This performance was largely driven by volume sales of its GLP1 franchise, and in particular Ozempic in the US, even though the latter came in marginally below expectations (Victoza compensated). The drug reached DKK 2...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.